Henry Ford Health Initiates Patient Enrollment for BioCardia’s CardiAMP HF II Pivotal Study for Ischemic Heart Failure of Reduced Ejection Fraction
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 16 2025
0mins
Source: Globenewswire
BioCardia's CardiAMP HF II Trial: BioCardia, Inc. has commenced patient enrollment at Henry Ford Health for its CardiAMP HF II trial, which aims to evaluate the safety and efficacy of autologous cell therapy in treating ischemic heart failure.
Heart Failure Statistics and Treatment: Approximately 6.2 million adults in the U.S. suffer from heart failure, with current treatments often inadequate; CardiAMP therapy seeks to enhance healing by using patients' own bone marrow cells to improve heart function.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
